In the past week, BSX stock has gone down by -0.68%, with a monthly gain of 4.82% and a quarterly surge of 8.23%. The volatility ratio for the week is 1.16%, and the volatility levels for the last 30 days are 1.50% for Boston Scientific Corp. The simple moving average for the past 20 days is 0.75% for BSX’s stock, with a 17.44% simple moving average for the past 200 days.
Is It Worth Investing in Boston Scientific Corp. (NYSE: BSX) Right Now?
The price-to-earnings ratio for Boston Scientific Corp. (NYSE: BSX) is above average at 67.44x, Company’s 36-month beta value is 0.80.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 10 as “overweight,” 6 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BSX is 1.47B, and currently, short sellers hold a 0.83% ratio of that floaft. The average trading volume of BSX on September 30, 2024 was 5.45M shares.
BSX) stock’s latest price update
Boston Scientific Corp. (NYSE: BSX)’s stock price has increased by 0.32 compared to its previous closing price of 83.08. However, the company has seen a -0.68% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-09-27 that Investors looking for stocks in the Medical – Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Analysts’ Opinion of BSX
Many brokerage firms have already submitted their reports for BSX stocks, with Goldman repeating the rating for BSX by listing it as a “Buy.” The predicted price for BSX in the upcoming period, according to Goldman is $90 based on the research report published on May 30, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see BSX reach a price target of $80, previously predicting the price at $65. The rating they have provided for BSX stocks is “Buy” according to the report published on February 01st, 2024.
Robert W. Baird gave a rating of “Outperform” to BSX, setting the target price at $59 in the report published on July 19th of the previous year.
BSX Trading at 5.38% from the 50-Day Moving Average
After a stumble in the market that brought BSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.81% of loss for the given period.
Volatility was left at 1.50%, however, over the last 30 days, the volatility rate increased by 1.16%, as shares surge +3.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.32% upper at present.
During the last 5 trading sessions, BSX fell by -0.68%, which changed the moving average for the period of 200-days by +50.83% in comparison to the 20-day moving average, which settled at $82.87. In addition, Boston Scientific Corp. saw 44.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BSX starting from Mahoney Michael F, who sale 162,777 shares at the price of $81.17 back on Sep 05 ’24. After this action, Mahoney Michael F now owns 1,622,987 shares of Boston Scientific Corp., valued at $13,212,544 using the latest closing price.
MICHAEL F MAHONEY, the Officer of Boston Scientific Corp., proposed sale 162,777 shares at $81.17 during a trade that took place back on Sep 05 ’24, which means that MICHAEL F MAHONEY is holding shares at $13,212,533 based on the most recent closing price.
Stock Fundamentals for BSX
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.67 for the gross margin
The net margin for Boston Scientific Corp. stands at 0.12. The total capital return value is set at 0.09. Equity return is now at value 9.46, with 5.16 for asset returns.
Based on Boston Scientific Corp. (BSX), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at 0.25. The debt to equity ratio resting at 0.52. The interest coverage ratio of the stock is 9.81.
Currently, EBITDA for the company is 3.62 billion with net debt to EBITDA at 2.05. When we switch over and look at the enterprise to sales, we see a ratio of 8.58. The receivables turnover for the company is 6.34for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.61.
Conclusion
In a nutshell, Boston Scientific Corp. (BSX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
